Losartan not found to reduce lung injury and mortality in patients with COVID-19
Researchers at University of Minnesota have found that a common blood pressure medication - losartan - is not effective in reducing lung injury in patients with COVID-19. Further it had no effect on mortality either.
The study was published in JAMA Network Open.
This drug was reported to benefit in preclinical models of the 2003 SARS virus, a close family member to the current SARS-CoV-2 virus. This study was conducted across 12 U.S. academic research institutions.
The U of M Medical School and School of Public Health research team sought to determine if a common blood pressure medication might decrease lung injury in patients admitted to the hospital with COVID-19. Their results found that losartan treatment did not reduce lung injury in patients admitted with COVID-19, and had no effect on mortality.
The researchers also found that critically-ill patients treated with losartan needed additional, temporary blood pressure support — though this did not lead to worse outcomes overall.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.